

Title (en)

PHARMACEUTICAL USES OF OPTICALLY PURE (+) -BUPROPION

Title (de)

PHARMAZEUTISCHE ANWENDUNGEN VON OPTISCH REINEM (+)-BUPROPION

Title (fr)

UTILISATIONS PHARMACEUTIQUES DE (+)-BUPROPION OPTIQUEMENT PUR

Publication

EP 1051166 A1 20001115 (EN)

Application

EP 99904433 A 19990128

Priority

- US 9901952 W 19990128
- US 7295598 P 19980129

Abstract (en)

[origin: WO9938502A1] Methods and compositions are disclosed utilizing the optically pure (+)-isomer of bupropion, which is a potent drug for treating depression, Parkinson's disease, obesity, weight gain, bipolar, attention-deficit or conduct disorders, psychosocial dysfunction, bulimia, eating disorders or specific food craving. The composition can be administered intravenously, transdermally (patch) or orally, possibly in a sustained release form.

IPC 1-7

A61K 31/135

IPC 8 full level

A61K 9/20 (2006.01); **A61K 9/22** (2006.01); **A61K 9/48** (2006.01); **A61K 9/52** (2006.01); **A61K 9/70** (2006.01); **A61K 31/135** (2006.01); **A61K 31/137** (2006.01); **A61P 1/14** (2006.01); **A61P 3/04** (2006.01); **A61P 15/10** (2006.01); **A61P 25/00** (2006.01); **A61P 25/14** (2006.01); **A61P 25/16** (2006.01)

CPC (source: EP)

A61K 31/135 (2013.01); **A61K 31/137** (2013.01); **A61P 1/14** (2017.12); **A61P 3/04** (2017.12); **A61P 15/10** (2017.12); **A61P 25/00** (2017.12); **A61P 25/14** (2017.12); **A61P 25/16** (2017.12)

Citation (search report)

See references of WO 9938502A1

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)

WO 9938502 A1 19990805; AU 2483499 A 19990816; CA 2318960 A1 19990805; EP 1051166 A1 20001115; JP 2002501890 A 20020122

DOCDB simple family (application)

US 9901952 W 19990128; AU 2483499 A 19990128; CA 2318960 A 19990128; EP 99904433 A 19990128; JP 2000529235 A 19990128